CLENPIQ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) by Ferring Pharmaceuticals is acidifying activity [moa]. First approved in 2017.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
CLENPIQ is an oral solution containing sodium picosulfate, magnesium oxide, and anhydrous citric acid approved by the FDA in November 2017. It functions through acidifying activity to dissolve calculi and is classified as a calculi dissolution agent. The product is indicated for bowel cleansing prior to colonoscopy and operates as a low-volume polyethylene glycol-free alternative in the gastrointestinal preparation market. It represents an innovation in colonoscopy prep formulations, offering patients a more tolerable option with reduced volume requirements.
Acidifying Activity
Calculi Dissolution Agent
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy
Effects and Tolerability With Clenpiq and Low Residue Diet
Comparison of Clenpiq vs Golytely Bowel Preparation
Currently, zero open positions are linked to CLENPIQ in active recruitment. Roles for this product typically include brand managers, field sales representatives, and medical science liaisons focused on gastroenterology and primary care markets. Success in supporting CLENPIQ requires expertise in gastrointestinal indication management, formulary navigation, and patient education around colonoscopy preparation protocols.
Worked on CLENPIQ at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo